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ABSTRACT
Individuals with anxiety disorders are significantly more likely to develop substance use
disorders than those without anxiety disorders (Kessler & Greenberg, 2002). Despite a sizeable
body of literature focused on etiological and maintenance factors underlying the co-occurrence
of substance use and anxiety pathology, this relationship remains poorly understood.
Transdiagnostic factors, specifically distress tolerance, anxiety sensitivity, and emotion-driven
impulse control difficulties, have been posited to contribute to the relationship of anxiety and
substance abuse, and in particular, nonmedical use of prescription drugs (NMUPD; Dennhardt &
Murphy, 2013; Wolitzky-Taylor et al., 2015). The current study examined group differences
among the aforementioned transdiagnostic factors, and whether they served as mediators in the
relation of anxiety and NMUPD in a sample of college students. Participants were 184
undergraduate students at the University of Mississippi who either engaged in past year NMUPD
or did not. All participants completed a battery of questionnaires and participated in a laboratory
task. Counter to the hypotheses, results indicated that there were not significant differences in the
transdiagnostic variables among the two groups, and that none of the transdiagnostic variables
mediated the relation of anxiety and NMUPD. Compared to non-drug users, drug users reported
more substance use overall, including polysubstance use, and reported more self-medication
motives for NMUPD than a similar sample of undergraduate students. The findings are
consistent with the extant literature indicating that college students who engage in past year
NMUPD are at increased risk for other substance abuse, including simultaneous polysubstance
use. Future studies should further examine risk factors for NMUPD among college students.
ii

ACKNOWLEDGMENTS
I would first like to express my deepest gratitude to my advisor, Dr. Laura Dixon, for her
invaluable help with this Thesis. Without your help and guidance, this project would not have
been possible. I would additionally like to thank my other committee members, Drs. Todd
Smitherman and Elicia Lair, for their insight and feedback on this project. Lastly, I would like to
thank my parents for their continuous support and encouragement throughout my life and for
helping me achieve my personal and career goals.

iii

TABLE OF CONTENTS
ABSTRACT ....................................................................................................................... ii
ACKNOWLEDGMENTS ................................................................................................ iii
LIST OF TABLES ..............................................................................................................v
LIST OF FIGURES .......................................................................................................... vi
INTRODUCTION ..............................................................................................................1
METHOD .........................................................................................................................12
RESULTS .........................................................................................................................25
DISCUSSION ...................................................................................................................29
REFERENCES .................................................................................................................38
APPENDICES ..................................................................................................................56
CURRICULUM VITA .....................................................................................................93

iv

LIST OF TABLES
1. Point-biserial Correlations of NMUPD and Study Variables ...............................87
2. Between Group Differences on Study Variables ..................................................88

v

LIST OF FIGURES
1. Conceptual Diagram of the Multiple Parallel Mediation Model ..........................90
2. Multiple Mediation Model of the Relation Between Anxiety and NMUPD, with Selfreported Anxiety Sensitivity, Distress Tolerance, and Emotion-driven Impulse Control
Difficulties ............................................................................................................91
3. Multiple Mediation Model of the Relation Between Anxiety and NMUPD, with Selfreported Anxiety Sensitivity and Emotion-driven Impulse Control Difficulties, and
Behaviorally Measured Distress Tolerance ..........................................................92

vi

INTRODUCTION
Anxiety disorders represent the most frequently occurring mental health disorders in the
United States, with a lifetime prevalence rate of 28.8% in the general population (Kessler, Chiu,
Demler, & Walter, 2005). Anxiety disorders are associated with significant economic burden and
negative outcomes, such as elevated risk of unemployment, lower income, and shortened
lifespan (Ettner, Frank, & Kessler, 1997; Jayakody, Danziger, & Kessler, 1998; Kessler &
Greenberg, 2002). In addition to these adverse consequences, higher rates of alcohol, nicotine,
and illicit drugs (e.g., cannabis, heroin) have been observed among individuals with anxious
pathology (Zvolensky & Schmidt, 2004). Indeed, individuals with anxiety disorders are 1.6 to
3.0 times more likely to develop substance use disorders (SUDs) than individuals without
anxiety disorders (Kessler & Greenberg, 2002).
The co-occurrence of anxiety disorders and SUDs is associated with greater symptom
severity and functional impairment than either disorder alone (Burns, Teesson, & O’Neill, 2005;
Magidson, Liu, Lejuez, & Blanco, 2012). Furthermore, co-occurring anxiety symptoms and
substance use have a higher prevalence than anxiety disorders alone (Zahradnik & Stewart,
2009). Epidemiological studies have found that 11.9% to 14.9% of individuals with anxiety
disorders have a comorbid SUD, and 17.7% to 33.5% of individuals with SUDs have a
concurrent anxiety disorder (Grant et al., 2004; Teesson, Slade, & Mills, 2009). Even though
research has focused on these frequently co-occurring conditions, more information is warranted
to determine which specific substances pose the greatest threat to individuals with pathological
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anxiety, and to identify characteristics relevant to anxiety that may amplify problematic
substance use.
Both theoretical and empirical evidence support the role of substance abuse as a way to
manage aversive emotional states and physiological arousal associated with anxiety (Morris,
Stewart, & Ham, 2005; Robinson, Sareen, Cox, & Bolton, 2011; Smith, Feldner, & Badour,
2011; Stewart & Conrod, 2008). Specifically, the self-medication hypothesis and tensionreduction models (herein collectively referred to as the self-medication hypothesis; Comeau,
Stewart, & Loba, 2001; Conger, 1956; Khantzian, 1985) posit that individuals engage in
substance misuse to reduce preexisting negative affect, such as anxiety symptoms. This theory is
based in negative reinforcement, wherein substances are used to reduce anxiety symptoms
(Davis, Witcraft, Baird, & Smits, 2017; Eissenberg, 2004; Smith et al., 2011). For instance, when
a person has an unpleasant internal experience, such as anxious arousal, distress, or negative
affect, s/he might engage in substance use (e.g., alcohol) to reduce the anxiety. Repeated over
time, this process creates a learning experience that drinking alcohol reduces anxiety; in other
words, drinking alcohol is negatively reinforced by the reduction in anxiety. However, when the
substance’s short-term effects subside, the chances of the person craving alcohol and drinking
alcohol to reduce anxiety is increased due to it being an effective anxiety-reduction strategy in
the individual’s learning history (Hayes, Wilson, Gifford, Follette, & Strosahl, 1996). Therefore,
this negative reinforcement cycle leads to long-term increases in frequency and intensity of
problematic substance use (Eissenberg, 2004; Khantzian, 1985).
In addition to the self-medication hypothesis literature, there is a growing body of
empirical and theoretical work that suggests the relation between anxiety and substance misuse
may be explained by common third variables or transdiagnostic factors (Tull, Baruch, Duplinsky,
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& Lejuez, 2008; Wolitzky-Taylor et al., 2015). Specifically, distress tolerance, anxiety
sensitivity, and emotion-driven impulse control difficulties have been found to each play a role
in the anxiety-substance abuse link (Allan, Macatee, Norr, Raines, & Schmidt, 2015; Howell,
Leyro, Hogan, Buckner, & Zvolensky, 2010; Kaiser, Milich, Lynam, & Charnigo, 2012; Stewart
& Kushner, 2001). First, distress tolerance describes the perceived ability or inability to
withstand distress and/or other negative emotional states (Simons & Gaher, 2005). Distress
tolerance has been associated with increased symptom severity across symptoms of panic
disorder, social anxiety disorder, obsessive-compulsive disorder, and anxious worry above and
beyond their relationship with general negative affect (Keough, Riccardi, Timpano, Mitchell, &
Schmidt, 2010). Additionally, individuals who have decreased levels of distress tolerance (i.e.,
intolerant of distress) are posited to engage in substance use to cope with negative affective
states, such as anxiety (Wolitzky-Taylor et al., 2016). For instance, Howell and colleagues
(2010) found that distress tolerance was uniquely related to coping-oriented motives for alcohol
use among young adult drinkers.
Although research in this area has primarily relied on self-report measures of distress
tolerance, a few studies have demonstrated that behavioral assessments of distress tolerance are
associated with negative affect and substance use. For example, Gorka and colleagues (2012)
used a behavioral measure of distress tolerance to investigate the role of distress tolerance in the
relation of problematic alcohol use and negative affect, finding that negative affect predicted
alcohol use problems in individuals with low, but not high, distress tolerance. Similarly,
Vujanovic and colleagues (2016) found that self-report and behavioral assessments of distress
tolerance were significantly correlated with posttraumatic stress disorder symptoms, above and
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beyond past month substance use, among participants who had experienced a potentially
traumatic event.
The second transdiagnostic factor important to the anxiety-substance abuse link is anxiety
sensitivity, which refers to the trait-like fear that the experience of anxiety will result in
catastrophic consequences, such as panic, illness, or social embarrassment (Reiss, Peterson,
Gursky, & McNally, 1986). Of note, factor analytic evidence suggests that distress tolerance and
anxiety sensitivity are related, yet distinct, as distress tolerance encompasses a wider range of
aversive states (e.g., sadness, anger) and maladaptive reactions to distress (e.g., behavioral,
emotional; Bernstein, Zvolensky, Vujanovic, & Moos, 2009; Howell et al., 2010; WolitzkyTaylor et al., 2015). Extensive empirical and theoretical research have established anxiety
sensitivity as a transdiagnostic factor across many psychopathologies, including anxiety and
problematic substance use (Boswell et al., 2013; Tull et al., 2008).
Numerous studies support the unique role of anxiety sensitivity in explaining the cooccurrence of anxiety and SUDs (Stewart & Kushner, 2001). For instance, Dixon and colleagues
(2014) found that high anxiety was positively associated with illicit substance abuse in
individuals with elevated anxiety sensitivity, but not in those with nonclinical levels of anxiety
sensitivity, suggesting that trait anxiety alone does not predict substance abuse. Consistent with
the self-medication hypothesis, anxiety sensitivity has been associated with increased substance
abuse frequency among inpatients with anxiety disorders (DeHaas, Calamari, & Bair, 2002), and
has been linked to coping-related motives for alcohol (Berenz et al., 2016), cannabis (BonnMiller, Zvolensky, & Bernstein, 2007), and nicotine (Gonzalez, Zvolensky, Vujanovic, Leyro, &
Marshall, 2008). In addition, anxiety sensitivity has been found to be integrally involved in the
relation of anxiety and substance misuse. One prospective study found that anxiety sensitivity
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uniquely predicted the development of alcohol use disorders over and above trait anxiety,
indicating that anxiety sensitivity may play a bigger role in the misuse of alcohol than anxiety
alone (Schmidt, Buckner, & Keough, 2007).
Lastly, emotion-driven impulse control difficulties refer to the propensity to engage in
undesired behavior, such as substance abuse and risky sex, when experiencing negative emotions
(Gratz & Roemer, 2004; Weiss, Tull, Anestis, & Gratz, 2013; Whiteside & Lynam, 2001).
Emotion-related impulsivity has been associated with anxiety, avoidance of anxiety, and
substance abuse (Acton, 2003; Weiss et al., 2013; Wolitzky-Taylor et al., 2015). With regard to
anxiety pathology, studies have found that negative urgency, or impulsivity driven by negative
affect, is associated with increased worry (Pawluk & Koerner, 2013), obsessions (Cougle,
Timpano, & Goetz, 2012), and increased engagement in risky behaviors among both anxious and
nonclinical samples (Guillot, Pang, & Leventhal, 2014; Weitzman, McHugh, & Otto, 2011).
Studies suggest that individuals with substance use disorders tend to use maladaptive emotion
regulation strategies, and have more emotion regulation deficits overall than those who do not
abuse substances (Fox, Axelrod, Paliwal, Sleeper, & Sinha, 2007; Fox, Hong, & Sinha, 2008;
Weiss et al., 2013). Additionally, it has been hypothesized that during emotional states, impulse
control may fail as a result of giving primacy to affect regulation during states of being
emotionally distraught (Tice, Bratslavsky, & Baumeister, 2001). For instance, following a sad
mood induction, when participants are not instructed that their mood will be stagnant, then they
tend to eat increased amounts of fatty foods in response to distress because they expect that
doing so will make them feel better (i.e., negative reinforcement; Tice et al., 2001).
Emotion-driven impulse control difficulties have been posited to have a causal
relationship with substance use, wherein increases in uninhibited impulsivity lead to increases in
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substance use during highly emotional states (Smith & Cyders, 2016). Prior studies have found
that elevated negative urgency is linked to increased cannabis use (Kaiser et al., 2012), nicotine
use (Guillot et al., 2014), and alcohol use (Menary et al., 2015). Additionally, negative urgency
has been found to moderate the relationship between anxiety sensitivity and smoking cessation
outcomes and abstinence expectancies (Guillot et al., 2014), as well as the effect of anxiety on
alcohol dependence (Menary et al., 2015).
Several investigations have examined distress tolerance, anxiety sensitivity, and emotiondriven impulse control difficulties in attempt to better understand anxiety and substance use. For
example, results from an empirical study investigating marijuana use suggest that both distress
tolerance and anxiety sensitivity contribute to different self-medication motives for use, as both
distress tolerance and anxiety sensitivity were related to coping-oriented motives, but only
anxiety sensitivity was related to conformity-oriented motives (Zvolensky et al., 2009). Another
study found that negative urgency accounted for significant variance in the relation between
anxiety sensitivity and smoking behaviors, suggesting that smokers high in anxiety sensitivity
are likely to react impulsively when experiencing negative affect compared to those lower in
anxiety sensitivity (Guillot et al., 2014). Lastly, a study examining substance use, distress
tolerance, and negative urgency in a sample of first-year college students found that only
negative urgency was significantly associated with all substance use outcomes (i.e., alcohol,
marijuana, tobacco, and illicit drugs), above and beyond trait negative affect (Kaiser et al., 2012).
Taken together, these findings further inform the self-medication model and suggest that distress
tolerance, anxiety sensitivity, and emotion-driven impulse control difficulties importantly
influence substance use. Unfortunately, the literature in this area is underdeveloped and few
studies have simultaneously examined these constructs in relation to anxiety and substance use.
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To date, only one study has concurrently examined the impact of distress tolerance,
anxiety sensitivity, and negative emotion-driven impulsivity on alcohol and cannabis use in
adolescents (Wolitzky-Taylor et al., 2016). This study demonstrated that negative emotiondriven impulsivity was the only significant, unique mediator in the relationship between anxiety
pathology and alcohol and cannabis use, after accounting for the effects of distress tolerance and
anxiety sensitivity (Wolitzky-Taylor et al., 2016). That is, higher levels of anxiety symptoms
were associated with greater alcohol-use and cannabis-use problems, respectively, through
increased impulsivity (Wolitzky-Taylor et al., 2016). These findings suggest that emotion-driven
impulse control difficulties may be particularly important in the relation between anxiety and
problematic substance use.
Research has primarily focused on understanding the associations between anxiety
pathology and alcohol and nicotine use, with fewer studies examining illicit substance (e.g.,
marijuana, heroin) and prescription medication abuse (Zvolensky & Schmidt, 2004). Notably,
prescription drug abuse is a rapidly increasing problem among adolescents and adults across the
world. Throughout the past ten years, the 12-month prevalence rate of abuse and dependence of
prescription drugs increased 67% (Blanco et al., 2007), which is largely a result of illegal use
rather than medical use (Arria & DuPont, 2010; Wu & Blazer, 2011; Young, Glover, & Havens,
2012). Indeed, the 2011 National Survey on Drug Use and Health (NSDUH) indicated that 6.1
million people aged twelve and older had used prescription drugs recreationally within the
previous month (Substance Abuse and Mental Health Services Administration [SAMHSA],
2015). Over this span of time, prescription drug abuse has come to represent a significant
economic burden (Birnbaum et al., 2006; Hansen, Oster, Edelsberg, Woody, & Sullivan, 2011),
and has been associated with a range of adverse outcomes including incarceration (Serxner,
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Gold, & Bultman, 2001), absenteeism (Birnbaum et al., 2006), and even death (Van Hasselt,
Keyes, Bray, & Miller, 2015).
The nonmedical use of prescription drugs (NMUPD) occurs when prescription
medications are obtained from a nonmedical source (e.g., a classmate), not taken as prescribed
(e.g., more than the prescribed dosage), or used for a nonmedical or recreational purpose (e.g., to
get high, to stay up later; Kelly, Rendina, Vuolo, Wells, & Parsons, 2015). The major categories
of frequently abused prescription drugs are stimulants (e.g., amphetamines), opioid pain relievers
(e.g., Oxycodone), and sedatives (e.g., anxiolytics; National Institute on Drug Abuse [NIDA],
2011). Holloway and Bennett (2012) posit two types of prescription drug misuse: 1) using a
prescribed medication in a way that was not intended; and 2) using prescription drugs that are
sold, traded, or given away. One study found that 17% of adolescents sold, traded, or gave away
their prescription, while 12% kept their prescription but used it in a way in which it was not
prescribed. In total, 40% of students reported some combination of the aforementioned misuse
(Holloway & Bennett, 2012). Consistent with these findings, another study found that 14.7% of
students reported giving their prescribed stimulant to friends (Poulin, 2001).
Although NMUPD is at an all-time high across all age groups, adolescents and young
adults (collectively referred to as youth) are especially vulnerable to misusing prescription
medication, largely because of the misconception that they are safe to abuse due to their
prescribed nature (Arria & DuPont, 2010; Wu & Blazer, 2011; Young et al., 2012). Indeed, a
study examining substance use patterns over the course of ten years indicated that the significant
increase in NMUPD is most notable among young adults between the ages of 18 and 34 (Blanco
et al., 2007). In 2013, the percentage of adolescents who reported recreational use of prescription
drugs on at least one occasion was approximately one-in-four, which is a 33% increase from
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2008 (NIDA, 2013). In addition, national survey data indicated that of individuals aged 18 – 25,
44% reported using prescription drugs and 15% reported misuse of prescription drugs in the past
year (SAMHSA, 2015). Prescription drugs are also quickly becoming one of the most commonly
used illicit drugs. On college campuses, NMUPD is second only to marijuana use (Grant et al.,
2004; Johnston, O’Malley, & Bachman, 2003), and NMUPD has increased four times more than
cannabis use disorders over the course of ten years (Blanco et al., 2007).
The increase in the rates of NMUPD among youth has been attributed to the overprescribing of prescription drugs and the ease of access (Centers for Disease Control and
Prevention [CDC], 2014; NIDA, 2013). Adolescents falsely believe that these drugs are safer
than illicit drugs because they are prescribed by medical professionals (Netemeyer, Burton,
Delaney, & Hijjawi, 2015), which may pose dangerous, unanticipated risks, such as negative side
effects and interactions with other substances (e.g., alcohol; McCabe, Boyd, & Teter, 2009).
Elevated levels of anxiety symptoms have been posited as a significant vulnerability of NMUPD
in youth (Blanco et al., 2007; Hall, Howard, & McCabe, 2010; McCabe et al., 2009; Viana et al.,
2012). Data collected from over 43,000 individuals found that those with a history of an anxiety
disorder were more likely to develop NMUPD than those without a history of anxiety (Blanco et
al., 2007). Similarly, one study found that individuals with clinically significant levels of panic
and social anxiety symptoms were two times more likely to be at risk for NMUPD than those
with nonclinical symptoms (Viana et al., 2012). In another study, health anxiety was shown to be
a risk factor for NMUPD (Jeffers et al., 2015). At the same time, negative emotion-driven
impulsivity has been shown to be associated with illicit substance use among college students
(Kaiser et al., 2012). Specifically, Blanchard and colleagues (2017) found that females reporting
NMUPD, both over the lifetime and within the past month, had significantly higher rates of
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negative emotion-driven impulsivity than those who did not report NMUPD. Together these
studies suggest that anxiety and related vulnerability factors may play a key role in NMUPD.
Given the increasing rates of NMUPD among youth, college students are a particularly
important population for informing risk prevention and intervention programs (Arria & DuPont,
2010; Blanco et al., 2007; Wu & Blazer, 2011; Young et al., 2012). College students present as a
uniquely vulnerable population due to the high rates of anxiety (Eisenberg, Gollust, Golberstein,
& Hefner, 2007), polysubstance drug abuse (Arria et al., 2008; McCabe, Teter, Boyd, Knight, &
Wechsler, 2005), and easy access to substances (Gliksman, 1988) that may occur at higher rates
in college as compared to other times throughout one’s life. Further, Blanchard and colleagues
(2017) found that emotion-related impulsivity differentially predicted nonmedical use of
depressants among college students. Accordingly, the purpose of the current study is to compare
transdiagnostic anxiety factors (i.e., distress tolerance and anxiety sensitivity) and emotiondriven impulse control difficulties between college students with and without NMUPD in the
past year.
Aim 1: To examine anxiety, trait variables, NMUPD, and related factors among a
sample of college students.
Hypothesis 1: NMUPD will be significantly positively associated with trait anxiety, distress
tolerance, anxiety sensitivity, and emotion-driven impulse control difficulties.
Hypothesis 2: Compared to individuals without past-year NMUPD, individuals with a
history of NMUPD will report significantly higher levels of anxiety, anxiety sensitivity, and
emotion-driven impulse control difficulties, and significantly lower levels of distress tolerance.
Additionally, reporters of NMUPD are expected to endorse more adverse outcomes that have
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been associated with NMUPD, such as stressful events, self-medication motives, and frequency
and diversity of substance use (Arria et al., 2008; McCabe et al., 2005, 2009).
Hypothesis 3: This study seeks to examine Wolitzky-Taylor et al.’s (2016) mediation
model in a cross-sectional sample of college students by examining the role of distress tolerance,
anxiety sensitivity, and emotion-driven impulse control difficulties in the relation between
anxiety and NMUPD. Wolitzky-Taylor and colleagues (2016) found a significant indirect effect
of negative emotion-driven impulsivity, but not distress tolerance and anxiety sensitivity, in the
relation between anxiety and substance misuse. Given prior work among college students (Ali,
Ryan, Beck, & Daughters, 2013; Berenz et al., 2016), it is expected that anxiety will be indirectly
associated with NMUPD through distress tolerance (both self-reported and behaviorally
measured), anxiety sensitivity, and emotion-driven impulse control difficulties. Furthermore, in
line with the extant literature (e.g., Guillot et al., 2014; Kaiser et al., 2012; Wolitzky-Taylor et
al., 2016), it is also predicted that the indirect effect of emotion-driven impulse control
difficulties will be more robust as compared to the indirect effects of distress tolerance and
anxiety sensitivity in the relation between anxiety and NMUPD.
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METHOD
Participants
Participants were 184 (Mage = 18.85, 75.5% female) undergraduate students who were
primarily in their freshman year of college (71.2%) recruited from the Department of
Psychology’s Sona Systems pool of undergraduate students at the University of Mississippi, a
large, southeastern public university. Participants were 71.7% White, 16.8% Black or African
American, 6.0% Asian, 3.8% biracial, and 1.6% other. Only 4.3% of participants identified as
Hispanic or Latino. All individuals who fell outside of the age range of 18 to 25 (i.e., emerging
adulthood) were excluded from the study (Arnet, 2000). Otherwise, participants were eligible.
Measures
The Alcohol Use Disorders Identification Test (AUDIT). The AUDIT (Babor,
Higgins-Biddle, Saunders, & Monteiro, 2001) is a 10-item self-report questionnaire developed
by the World Health Organization to screen for harmful and hazardous alcohol use. Items are
rated on a 5-point Likert scale from 0 to 4, with higher scores indicating more frequent use and a
broader domain of interference. A clinical cutoff value of eight distinguishes hazardous drinking
from more serious harmful drinking. The AUDIT has three subscales: hazardous alcohol use
(e.g., “how many drinks containing alcohol do you have on a typical day when you are
drinking?”), symptoms of dependence (e.g., “how often during the last year have you found that
you were not able to stop drinking once you had started?”), and harmful alcohol use (e.g., “have
you or someone else been injured as a result of your drinking?”). The AUDIT has demonstrated
good construct validity via its correlation with alcohol use risk factors, reasons for drinking,
12

negative affect, and withdrawal symptoms (Bohn, Babor, & Kranzler, 1995). Additionally, the
AUDIT is able to differentiate alcoholics from non-alcoholics, and demonstrates superior
discriminant ability over and above the Michigan Alcoholism Screening Test (Bohn et al., 1995).
In the current study, the AUDIT demonstrated adequate reliability (Cronbach’s α = 66). See
Appendix A for the AUDIT.
Anxiety Sensitivity Index – 3 (ASI-3). The ASI-3 (Taylor et al., 2007) is an 18-item
self-report measure of anxiety sensitivity severity and frequency. Anxiety sensitivity is measured
on a 5-point Likert scale from 0 (“very little”) to 4 (“very much”). The ASI-3 assesses the
potential catastrophic physical, cognitive, and social consequences of anxiety. The suggested
clinical cutoff for the ASI-3 is a total score of 23, which indicates clinically significant levels of
anxiety sensitivity, and suggests impairment or distress due to symptoms (Allan, Korte, Capron,
Raines, & Schmidt, 2014; Allan, Raines, et al., 2014). The ASI-3 subscales have demonstrated
good convergent and divergent validity, as they have been shown to be highly correlated with the
original Anxiety Sensitivity Index, such that correlations among similar subscales were
significantly larger compared to correlations among dissimilar subscales (Taylor et al., 2007).
The ASI-3 further demonstrates convergent and divergent validity by its ability to distinguish
individuals with general anxiety and depressive symptoms (high associations) from those with
psychosis and self-harming behaviors (low associations) in a sample of highly comorbid
individuals (Rifkin, Beard, Hsu, Garner, & Björgvinsson, 2015). The ASI-3 has demonstrated
good to excellent internal consistency overall (Cronbach’s α = .93) in both clinical and
undergraduate samples (Wheaton, Deacon, McGrath, Berman, & Abramowitz, 2012). However,
in the current study, the ASI-3 demonstrated poor reliability (α = .58). See Appendix B for the
ASI-3.
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College Student’s Stressful Event Checklist (CSSEC). The CSSEC (Holmes & Rahe,
1967) is a self-report measure of the presence of 32 stressful events experienced by college
students. Participants place an “X” beside events that they have experienced or events that they
expect to occur soon. Each event has a predetermined rank and corresponding value (20 to 100,
20 being the lowest ranked event and 100 being the highest ranked event) that reflects the
severity of the event. For example, “death of a close family member” is ranked number one and
assigned the highest value of 100, while “minor traffic violations” is ranked 32 and assigned the
lowest value of 20. All event values are summed for a total score, which indicates mild (< 150),
moderate (150 to 300), or severe (> 300) stress. The CSSEC is adapted from Holmes and Rahe’s
(1967) Social Readjustment Rating Scale (SRRS), which is designed for an adult population, and
as such the items are tailored to adulthood stressors (e.g., divorce, fired at work, son or daughter
leaving home). The original SRRS evidenced adequate interrater reliability (Kendall’s
coefficient of concordance = 0.48; Holmes & Rahe, 1967). In the present study, the CSSEC
demonstrated adequate internal consistency (α = .74). See Appendix C for the CSSEC.
Depression Anxiety Stress Scale – 21 (DASS-21). The DASS-21 (Lovibond &
Lovibond, 1995) is a 21-item self-report measure of symptoms associated with depression,
anxiety, and stress. Items are rated on a 4-point Likert scale from 0 (“did not apply to me at all”)
to 3 (“applied to me very much, or most of the time”), with higher scores indicating greater
levels of distress. The DASS-21 is adapted from the 42-item DASS, and as such, scores on the
21-item version are doubled so as to make interpretation equivalent across the two versions. The
anxiety subscale (e.g., “I experienced trembling (e.g., in the hands)”) measures physiological
symptoms of anxiety, while the stress subscale (e.g., “I found myself getting agitated”) measures
cognitive symptoms of anxiety. The current study only used the 7-item anxiety subscale of the
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DASS-21. The DASS-21-Anxiety has displayed good psychometric properties in individuals
diagnosed with an anxiety or depressive disorder, by demonstrating good internal consistency (α
= .87) and concurrent validity (Antony, Bieling, Cox, Enns, & Swinson, 1998). In the current
study, the DASS-21-Anxiety evidenced adequate internal consistency (α = .68). See Appendix D
for the DASS-21-Anxiety.
Difficulties in Emotion Regulation Scale (DERS). The DERS (Gratz & Roemer, 2004)
is a 36-item self-report measure of emotion regulation difficulties. Items are rated on a 5-point
Likert scale from 1 (“almost never”) to 5 (“almost always”), with higher scores indicating more
difficulties regulating emotions. The DERS consists of six subscales, including nonacceptance of
emotional responses, difficulties engaging in goal-directed behavior, impulse control difficulties,
lack of emotional awareness, limited access to emotion regulation strategies, and lack of
emotional clarity. In the current study, the 6-item impulse control difficulties subscale (DERSImpulse) was used as a measure of emotion-driven impulse control difficulties. Test-retest
reliability for the DERS-Impulse was adequate (ρ = .57) in a sample of undergraduate students
(Gratz & Roemer); however, the test-retest sample only consisted of 21 participants, which
might account for low reliability. Further, the DERS-Impulse has demonstrated good predictive
validity (Gratz & Roemer, 2004) and has been positively associated with other measures of
emotion-driven impulse control difficulties (r = .64; Weiss et al., 2013). In the current study, the
DERS-Impulse evidenced adequate internal consistency (α = .68). See Appendix E for the
DERS-Impulse.
Distress Tolerance Scale (DTS). The DTS (Simons & Gaher, 2005) is a 15-item selfreport measure of distress tolerance, or the perceived ability to handle distress. Raters indicate to
what extent they agree with each item on a 5-point Likert scale from 1 (“strongly agree”) to 5
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(“strongly disagree”), with higher scores indicating greater ability to tolerate distress. The DTS is
comprised of four subscales: tolerance (perceived ability to tolerate and endure emotions),
absorption (attention that is occupied by emotions), appraisal (assessment of emotions as
acceptable), and regulation (perceived ability to manage emotions). Further, Simons and Gaher
(2005) found that the DTS demonstrated good divergent validity, as it is negatively associated
with measures of affective distress (r = -.59) and affective lability (r = -.52). Additionally, the
DTS was positively correlated with measures of mood acceptance (r = .47) and negative mood
regulation (r = .54), indicating convergent validity (Simons & Gaher, 2005). Lastly, the DTS has
also been shown to be negatively related to measures of alcohol and marijuana use, such that
increased distress tolerance was associated with decreased use of alcohol (r = -.23) and
marijuana (r = -.20; Simons & Gaher, 2005). The DTS has shown adequate test-retest reliability
(r = .61; Simons & Gaher, 2005) in undergraduates and excellent internal consistency in the
current study (α = .91). See Appendix F for the DTS.
Marlowe-Crowne Social Desirability Scale – Short Form (M-C). The M-C short form
(Reynolds, 1982) is an abbreviated version of the original 33-item scale (Crowne & Marlowe,
1960). This 13-item true/false self-report questionnaire assesses social desirability, or the
tendency to influence one’s scores by “faking good” or “faking bad” in order to present the way
that is expected of the participant (Meehl & Hathaway, 1946). Lower scores represent less
response bias, whereas higher scores represent greater social desirability. Previous studies
investigating prescription opioid abuse have used the M-C as a measure of social desirability
(e.g., Butler et al., 2007), and one found that individuals reporting less social desirability were
typically men who reported craving their prescribed opioids (Wasan et al., 2009). In the current
study, the M-C was used to examine social desirability, which may affect responding given the
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sensitive questions on drug use. Consistent with its use in prior work, it would be expected that
individuals in the non-drug use group would report higher social desirability, which would
indicate potential inaccurate responding (Reynolds, 1982). The 13-item M-C has demonstrated
excellent convergent validity with the original 33-item M-C (r = .93; Reynolds, 1982).
Moreover, the 13-item short form has demonstrated adequate incremental validity (rKR-20 = .76)
that is comparable to the original 33-item. However, in the current study, the M-C demonstrated
poor reliability (α = .36), and results should be interpreted with caution. See Appendix G for the
M-C.
Nonmedical Prescription Drug Motives Questionnaire (NMPD-MQ). The NMPDMQ (Milner, 2015) is a 20-item self-report questionnaire assessing motives for using
prescription drugs nonmedically. Items are rated on a 5-point Likert scale from 1 (“almost
never/never”) to 5 (“almost always/always”). Items are adapted from the Modified Drinking
Motives Questionnaire – Revised (DMQ-R; Cooper, 1994) and the Marijuana Motives Measure
(Simons, Correia, Carey, & Borsari, 1998). The NMPD-MQ has four subscales determined by
factor analysis: Self-medication (e.g., “to escape from your life”), social/recreation (e.g.,
“because it gives you a pleasant feeling”), performance (e.g., “to help focus”), and conformity
(e.g., “so that others won’t kid you about not doing it”). In an unpublished dissertation, Milner
(2015) demonstrated convergent validity, evidenced by positive correlations between the selfmedication subscale and the DMQ-R coping subscale, the social/recreation subscale and the
DMQ-R enhancement subscale, the performance subscale and the DMQ-R social subscale, and
the conformity subscale and the DMQ-R conformity subscale. In addition, this study
demonstrated divergent validity for the NMPD-MQ as each subscale was negatively correlated
with other dissimilar measures (e.g., self-medication was negatively related to positive affect and
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sensation seeking). The NMPD-MQ demonstrated excellent internal consistency overall (α = .94)
in the current sample of college students. See Appendix H for the NMPD-MQ.
Use of Prescription Drugs Questionnaire. As there is no standardized measure to assess
NMUPD broadly, this questionnaire was developed by the author to measure NMUPD. Items
included: type of drug(s) used, type of use (i.e., using as prescribed or nonmedical use),
frequency and quantity of use, and polysubstance drug use. The primary outcomes of interest
include dichotomous reporting of past-year NMUPD (i.e., yes/no) and the frequency of NMUPD
(i.e., “never” to “multiple times a day”). Additionally, all participants were asked to list the
medication(s) used in the past year and indicate under which circumstances the medication was
used within the respective classification (i.e., stimulants, sedatives, opioid painkillers). See
Appendix I for the Use of Prescription Drugs Questionnaire.
Sociodemographic Questionnaire and General Medical History. Participants reported
their age, sex, race and ethnicity, year in school, current GPA, number of courses taken in the
semester of their participation, major, and health insurance status. Also, participants reported
substance use over the past year (i.e., alcohol, caffeine, tobacco, illicit drugs) and medical
history, including items assessing lifetime occurrence of common medical problems, current or
lifetime enrollment in therapy, and past-year prescribed and over-the-counter medications. See
Appendix J for the Sociodemographic Questionnaire and General Medical History.
Mirror Tracing Persistence Task – Computerized (MTPT-C). The MTPT-C (Strong
et al., 2003) is a behavioral task designed to elicit psychological distress and to measure goaldirected action in the context of distress. Participants are instructed to trace three increasingly
difficult geometric shapes on a computer screen. Unbeknownst to the participant, the computer
mouse is programmed to move in the opposite direction of its physical movement. When a
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participant deviates from the line s/he is supposed to trace or stops moving the mouse for two
seconds, a loud buzzer sounds and s/he is forced to begin the level again. Participants are given
the option to quit at the fourth presentation of the geometric shape, which is the same level of
difficulty as the previous shape (i.e., difficult). The first three rounds each last for one minute,
while the fourth lasts up to seven minutes depending on when the participant quits the task. The
primary outcome is latency to quit, which is measured in seconds.
The MTPT-C has evidenced convergent validity in a depressed sample, such that
depressed individuals terminate the task more quickly than non-depressed individuals (Ellis,
Vanderlind, & Beevers, 2013). Further, there is evidence of predictive validity in that persistence
on the MTPT-C can predict smoking cessation success, such that individuals who persist longer
have more successful quit attempts (Steinberg et al., 2012). Behavioral measures of
physiological and cognitive distress tolerance have been shown to be correlated with each other
(McHugh et al., 2011; McHugh & Otto, 2011). However, the literature broadly indicates that
behavioral measures of distress tolerance are poorly correlated with self-reported measures of
distress tolerance. Indeed, both Glassman et al. (2016) and McHugh et al. (2011) found that the
DTS and MTPT-C were not correlated (r = .05 and r = .07, respectively). This discrepancy
suggests that there may be differences in the constructs assessed by the self-report and behavioral
measures. Alternatively, the term “distress tolerance” may be multifaceted and comprise
cognitive and physiological components of tolerating distress.
Procedure
Overview. The study protocol received approval from the University of Mississippi’s
Institutional Review Board (IRB). All eligible participants were categorized in either the drug
use or non-drug use group, and both groups completed a laboratory session including

19

questionnaires and the MTPT-C. Participants earned 1.0 hours of course credit for their
participation.
Recruitment. Students in psychology courses enrolled in the study via Sona Systems, an
online study recruitment pool. An initial screening measure was included in the Sona screener to
assess for past-year use of prescription drugs. Past-year use of prescription drugs was assessed
rather than past-year nonmedical use due to the inclination of participants to provide inaccurate,
yet socially desirable responses to these questions that may result in high rates of false negatives,
as well as potential IRB concerns about confidentiality in the Sona screener and the illegal nature
of NMUPD. Eligible participants were identified and invited via e-mail to sign up for the study,
and those who reported using prescription drugs in the past year were encouraged to participate
to ensure adequate power in the drug use group.
Group Identification. Upon entering the lab, the informed consent process was reviewed
with the participants by a trained research assistant. Written informed consent was obtained from
interested individuals. First, participants completed the Use of Prescription Drugs Questionnaire
(see Appendix I). Upon completion of the questionnaire, research assistants determined whether
participants’ reported drug use met criteria for the drug use group or the non-drug use group. The
drug use group was determined in accordance with the definition of NMUPD, which consisted of
five items from the Use of Prescription Drugs Questionnaire. Participants who responded “yes”
to using prescription medications 1) not prescribed to them, 2) taken beyond the amount they
were told to take, and 3) for reasons other than how they were prescribed were assigned to the
drug use group. Additionally, if participants reported using nonmedically or recreationally on at
least one occasion within the past year or using more than the prescribed dosage (i.e., ≥ 1.5 times
the prescribed dosage), they were classified in the drug use group. In the case of an individual
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who initially reported no prescription drug use on the screener and then reported NMUPD in the
lab, this individual was included in the drug use group. The non-drug use group was comprised
of participants who reported no prescription drug use or abuse and/or reported medical use in the
past year.
Group assignment into the drug and non-drug use groups were checked by multiple
investigators to ensure fidelity to the definition of NMUPD and to address anomalies, including
unclear responding to NMUPD items. The study’s principal investigator and co-investigator
discussed discrepancies in group assignment based on predetermined decision rules. Drug use
information was kept separate from outcome data; therefore, all coders were blind to how the
participant responded to key variables, thereby reducing potential bias when resolving
discrepancies. See Appendix K for the group assignment flowchart.
Laboratory Session Procedures. Participants completed a brief packet of online
questionnaires via Qualtrics, including the AUDIT, ASI-3, CSSEC, DASS-21-Anxiety, DERSImpulse, DTS, M-C, NMPD-MQ, and the Sociodemographic Questionnaire and General Medical
History (see Appendices A through H and J). Then participants participated in the MTPT-C
(Strong et al., 2003). Upon completion of the laboratory session study procedures, participants
received a debriefing describing the purpose of the study.
In regard to the setting of the laboratory session, between one and ten participants
completed the study at a time. A step was taken early in data collection to protect participants’
confidentiality, such that participants turned in the Use of Prescription Drugs Questionnaire in an
manila envelope labeled “confidential.” Additionally, participants wore headphones or earphones
during the MTPT-C in order to reduce ambient noise.
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Data Analysis
Power Analysis. Preliminary data collection suggested a medium between-groups effect
size (Cohen’s d = .61) on the ASI-3. These data were used to conduct an a priori power analysis,
which indicated that, for independent samples t-tests, a sample size of at least 86 participants, 43
per group, was required to observe a medium between-group effect size using the parameters of a
two-tailed test with alpha level of .05 and power of .80 (G*Power; Erdfelder, Faul, & Buchner,
1996). Further, a review of the literature suggests that in order to achieve .80 power, a sample
size of approximately 143 is needed to detect mediation (Fritz & MacKinnon, 2007).
Data Cleaning Procedures. Statistical analyses were performed using SPSS Version 25
(IBM Corp., 2017). Data were screened for accuracy errors, missing data, outliers, and
assumptions. Of the 193 original participants, one participant was excluded for being outside of
the appropriate age range, two participants were excluded for discrepant group assignment data,
and six multivariate outliers were excluded using Mahalanobis distance. Data additionally met
assumptions of multicollinearity, normality, linearity, homogeneity, and homoscedasticity. The
final sample consisted of 184 participants, 115 in the non-drug use group and 69 in the drug use
group. Between-group analyses were conducted to examine potential differences between the
two groups that may have affected responses with regard to demographics and social desirability.
Sample Characteristics. Type of misuse, frequency of use, and concurrent use of other
substances were examined among the drug use group, and use of prescription drugs in general
was examined among the full sample, including frequency of classes of prescription drugs used
(i.e., stimulants, sedatives, and opioids), other prescribed medication (e.g., antidepressants), and
alcohol and illicit drug use.
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Examination of Hypotheses 1 and 2. Point-biserial correlations were used to test
associations between NMUPD and transdiagnostic variables (Hypothesis 1). Next, a series of
independent samples t-tests were conducted to test Hypothesis 2 that compared to individuals
without past-year NMUPD, individuals engaging in NMUPD would report significantly higher
levels of anxiety, anxiety sensitivity, and emotion-driven impulse control difficulties, and
significantly lower levels of distress tolerance, in addition to greater occurrence of stressful life
events and greater diversity of substance use. Additional independent samples t-tests were
utilized to examine group differences in alcohol use and polysubstance use (i.e., using another
substance simultaneously with prescription drugs). Further, self-medication motives were not
examined in the non-drug use group since this measure is only relevant to individuals who
misuse prescription drugs. Therefore, Spearman correlations were used to assess the association
between self-medication motives and frequency of prescription drug use, while a one sample ttest was utilized to compare the self-medication motive mean of the current study to that of
college-age prescription drug users from another study (Milner, 2015).
Hypothesis 3 (Multiple Parallel Mediation). Multiple parallel mediation models were
used to test Hypothesis 3, that anxiety would be associated with NMUPD via anxiety sensitivity,
distress tolerance, and emotion-driven impulse control difficulties (see Figure 1). In multiple
parallel mediation each mediator is simultaneously entered, which allows for each mediator to be
examined while at the same time, accounting for shared variance between the other mediators.
The PROCESS version 2.16 macro for SPSS was used to test the multiple mediation models
(Hayes, 2013). PROCESS uses ordinary least squares regression with bootstrapping to estimate
the indirect effects and to obtain confidence intervals for mediation models. Bias-corrected
bootstrapping of 10,000 re-samples were used to calculate unstandardized beta (b) coefficients,
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standard errors (SE), and 95% confidence intervals (95% CI) for all indirect (paths a1*b1, a2*b2,
and a3*b3), direct (path c’), and total effects (path c). Confidence intervals that contain zero
signify non-significant effects indicating that mediation is not present.
Two parallel mediation models were tested to examine the relation of anxiety and
NMUPD through various transdiagnostic mediators. The first model examined self-reported
anxiety sensitivity, distress tolerance, and emotion-driven impulse control difficulties as
mediators. The second model differed only in that behaviorally measured distress tolerance,
rather than self-reported distress tolerance, was tested as a mediator.
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RESULTS
Participant Characteristics
Chi-square goodness of fit and independent samples t-tests were used to test group
differences in sex, age, and ethnicity, which indicated that there were no significant differences
between groups (all p’s > .21). Social desirability was examined between the two groups as a
potential confounding factor, and findings indicated that the drug use group reported more social
desirability (M = 8.07, SD = 1.76) than the non-drug use group (M = 7.39, SD = 2.35; t (173.11)
= -2.24, 95% CI [-1.28 – -0.08], p = .027).
In total, 37.5% (n = 69) of the sample reported past-year NMUPD. Of these participants,
34.8% reported misusing their own prescription by using more than the prescribed dose and
29.0% used for reasons other than prescribed. Additionally, 59.4% reported using a medication
that was not prescribed to them. With regard to NMUPD frequency, 29.0% reported doing so
once, 27.5% reported monthly, 7.2% reported weekly, 5.8% reported 2 – 3 days a week, 14.5%
reported daily, 2.9% reported multiple times a day, and 1.4% reported nonmedical use
“randomly.” Lastly, 40.6% of the drug use group endorsed simultaneous polysubstance use,
mixing prescription medication with other substances (i.e., primarily alcohol and marijuana).
Among the total sample, 29.9% reported use of stimulants in the past year, which was
primarily comprised of Adderall. In addition, 12.5% of the sample reported use of sedatives,
including sleeping pills such as Trazodone and Ambien, and antianxiety medication such as
Xanax and Klonopin. Lastly, 15.8% of the sample reported use of opioids, which primarily
included hydrocodone. Notably, not all participants provided this information even if they did
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report using prescription drugs. Furthermore, it is conceivable that college students may
not know whether or not their use qualifies as abuse, and further, they may not know the exact
medication and dose that they are using. Of the total sample, 10.3% reported past-year use of
other prescribed medications, including antidepressants (i.e., citalopram), headache medication
(i.e., Topamax), and over-the-counter pain relievers (e.g., naproxen). Regarding alcohol use,
9.2% of the sample scored in a range indicative of potential alcohol abuse, which is considerably
lower than a nationally representative sample of undergraduate students (i.e., 31.6%; Knight et
al., 2002). Indeed, the median frequency of past-year alcohol use was “less than monthly,”
indicating that half of the sample reported never using alcohol in the past year, and half reported
using monthly or weekly. Additionally, 16.1% of the entire sample reported past-year illicit drug
use, including marijuana (16.5%), cocaine (2.3%), and hallucinogens (0.6%).
Regarding psychological characteristics, the overall sample endorsed a low level of
anxiety (M = 1.89, SD = 3.34) which fell in the normal range, a subclinical level of anxiety
sensitivity (M = 15.97, SD = 4.90), and a “severe” level with regard to stressful events
experienced (M = 410.44, SD = 182.19). Further, scores on the DERS-Impulse (M = 11.77, SD =
5.10) and DTS (M = 48.66, SD = 12.50) were consistent with other studies using these measures
with college-age participants (respectively, Gratz & Roemer, 2004; Anestis, Selby, Fink, &
Joiner, 2007). The sample, on average, did not report a hazardous level of drinking, and reported
very little illicit drug use outside of NMUPD.
Test of Study Hypotheses
Zero-order Correlations and Group Differences. See Table 1 for zero-order
correlations and descriptive statistics among primary variables. The first hypothesis was not
supported, such that NMUPD was not significantly associated with any of the transdiagnostic

26

variables (all p’s > .05). As expected, the transdiagnostic variables were significantly associated
with one another (all p’s < .001), and NMUPD was associated with both alcohol use (rpb = .401,
p, < .001) and illicit drug use (rpb = .373, p, < .001). Consistent with previous studies, selfreported and behaviorally measured distress tolerance were not significantly correlated with one
another (r = .060, p > .05). Contrary to the second hypothesis, none of the transdiagnostic
variables were significantly different between the drug and non-drug use groups, nor were
occurrence of stressful events (see Table 2).
Diversity of drug type was significantly different between the two groups, such that
individuals who engaged in past year NMUPD reported more diversity of drug use (M = 2.14,
SD = 1.67), including illicit drugs and alcohol, than individuals who reported medical or no use
(M = 0.71, SD = 0.97). Additionally, there was a significant difference between individuals who
abused prescription drugs and those who did not in alcohol use and polysubstance use behaviors.
Specifically, those engaging in NMUPD reported more alcohol (M = 4.17, SD = 3.55) and
polysubstance use (M = 0.41, SD = 0.50) than the non-drug use group (Malc = 1.57, SDalc = 2.44;
Mpoly = 0.04, SDpoly = 0.21; see Table 2). Lastly, self-medication motives for prescription drug
use was significantly associated with NMUPD frequency (ρ = .252, p = .037), and was
significantly higher than a large sample of undergraduate students who reported lifetime
prescription drug use, (t (68) = 12.89, 95% CI [6.04 – 8.26], p < .001). Specifically, the current
sample reported a mean of 9.02 (SD = 4.61) compared to the validation mean of 1.86 (SD =
1.05).
Multiple Parallel Mediation. Regarding the third hypothesis, the first parallel mediation
model analyses revealed that the a1, b1, and c1 paths were significant (see Figure 2 for the results
of each path of the first model). However, the indirect paths from anxiety to NMUPD through
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anxiety sensitivity (b = -0.0184, SE = 0.0362, 95% CI [-0.0893 – 0.0525]), distress tolerance (b =
-0.0086, SE = 0.0162, 95% CI [-0.0403 – 0.0230]), and emotion-driven impulse control
difficulties (b = 0.0302, SE = 0.0403, 95% CI [-0.0487 – 0.1091]) were not significant,
indicating no evidence of mediation. Similarly, the second model examining behavioral distress
tolerance indicated significant b1 and c1 paths, but a nonsignificant a1 path (see Figure 3 for the
result of each path of the second model). Further, the model yielded a nonsignificant indirect
effect from anxiety to NMUPD through anxiety sensitivity (b = -0.0158, SE = 0.0346, 95% CI [0.0835 – 0.0520]), distress tolerance (b = -0.0006, SE = 0.0020, 95% CI [-0.0045 – 0.0034]), and
emotion-driven impulse control difficulties (b = 0.0497, SE = 0.0373, 95% CI [-0.0234 –
0.1228]), indicating no evidence of mediation.1

1

Single mediation models examining each mediator variable independently were also examined and yielded the
same pattern of null findings.

28

DISCUSSION
Rates of nonmedical use of prescription drugs (NMUPD) have increased across all age
groups, but are especially high among young adults (Blanco et al., 2007). As such, the current
study aimed to further the understanding of NMUPD in college students by examining risk
factors that are known to contribute to both substance use and anxiety. The findings bring to light
the seriousness of the nonmedical use of prescription drugs, and particularly, the high frequency
in which it occurs in college students as well as concurrent use with other substances. In this
sample, nearly 40% reported past-year NMUPD, which is considerably higher than national
averages (15%; SAMHSA, 2015). Although it is possible that the rate of NMUPD in this sample
is uncharacteristically high due to the targeted recruitment of individuals who reported use of
prescription drugs, this finding is not unprecedented as another study found that the rate of
NMUPD among undergraduates in the past three months was 48% (Holloway & Bennett, 2012).
Consistent with literature (e.g., Huang et al., 2006), the most frequently endorsed class of
prescription drug was stimulants, which was about twice as high as the next most frequent class,
opioids, with sedatives being the least commonly used medication. The majority of participants
who engaged in NMUPD did so by using medications that were not prescribed to them, while a
smaller portion misused their own prescription medication. Similarly, prior work found that
approximately one-third of university students have reported using prescription drugs that are not
their own, while 23% reported misusing their own prescription and 11% sold, traded, or gave
away their prescribed medication (Holloway & Bennett, 2012). Of students who reported
NMUPD in the current sample, 40% endorsed simultaneous polysubstance use.
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This rate closely reflects large samples of undergraduates who used prescription drugs
and alcohol simultaneously (56.8%; McCabe, Cranford, Morales, & Young, 2006).
In the current study, point-biserial correlations were examined among past-year NMUPD
and relevant transdiagnostic vulnerability factors (i.e., anxiety sensitivity, distress tolerance,
emotion-driven impulse control difficulties). Contrary to our first hypothesis, these
transdiagnostic variables were not significantly associated with NMUPD. However, past-year
use of NMUPD was associated with all substance use variables, including alcohol use and use of
illicit drugs. Interestingly, counter to prior work, alcohol and illicit drug use were similarly not
correlated with the transdiagnostic variables (Simons & Gaher, 2005; Simons, Gaher, Correia,
Hansen, & Christopher, 2005).
The second hypothesis examined differences among individuals who reported past-year
NMUPD and those who reported medical use or no use. Specifically, we examined group
differences among trait anxiety, anxiety sensitivity, distress tolerance, and emotion-driven
impulse control difficulties, as well as the presence of stressful events, diversity of substance use,
and how NMUPD relates to self-medication motives. Contrary to the hypothesis, there were no
significant differences between individuals who engaged in past-year NMUPD and those who
did not on anxiety, the three transdiagnostic vulnerabilities, or occurrence of stressful events.
However, the finding that alcohol and illicit drug use is more than doubled among prescription
drug abusers compared to nonusers is consistent with literature that suggests that likelihood of
alcohol and illicit drug use disorders is increased for individuals reporting lifetime NMUPD
(Huang et al., 2006). Additionally, correlational findings and mean comparison to a similar
sample (Milner, 2015) suggest that students may engage in NMUPD as a self-medication
strategy.
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Findings suggest that students reporting past-year NMUPD are more likely to engage in
heavier alcohol consumption and simultaneous polysubstance use than their abstinent
counterparts. Further, over half of students reporting NMUPD also reported simultaneous
polysubstance use, most prominently alcohol. Despite the overall low rates of alcohol and illicit
drug use in the current study compared to representative samples, the results suggest that
NMUPD is associated with substance use generally, and in particular, with higher rates of
alcohol, illicit drug, and simultaneous polysubstance use. This high rate and the increased rate of
alcohol use in the NMUPD group is particularly alarming given that prescription drugs with
sedative qualities (e.g., benzodiazepines, opioid painkillers) augment the depressogenic effects of
alcohol, which can to lead to reduced respiratory function or failure and potentially overdose
and/or death (White & Irvine, 1999).
Although we would expect anxiety to be on a continuum, trait anxiety lacked variability
in the current study, such that the mean level anxiety was very low (see Osman et al., 2012;
Table 2), with 63.6% of the sample reporting no anxiety (0 out of possible 21). As such, it is
conceivable that prescription drugs, or substances in general, were not used to cope with
problematic anxiety, as the sample, on average, did not experience problematic anxiety. Lastly,
both prescription drug abusers and nonusers fell within the “severe stress” category regarding
occurrence of stressful events, which reflects the literature stating that college is a time of
increased stress (Misra & Castillo, 2004; Misra, McKean, West, & Russo, 2000), and could be
an explanation as to why there was not a significant difference in occurrence of stressful events.
Additionally, this measure rank orders stressful events from most (i.e., death of a close family
member) to least stressful (i.e., minor traffic violations). Potentially, students experienced similar
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events at roughly equal rates (e.g., “first semester in college,” “problems with a girlfriend or
boyfriend”), which may have resulted in scores being equivalent between the two groups.
The third hypothesis tested anxiety sensitivity, distress tolerance (both self-report and
behavioral), and emotion-driven impulse control difficulties as parallel mediators of the relation
of anxiety and NMUPD. Contrary to expectations, none of the transdiagnostic variables mediated
the relationship. However, the sample may be limited in that there is limited variance in the
outcome variable, and NMUPD was measured dichotomously rather than continuously.
Moreover, it may be difficult for the hypothesized mechanisms (i.e., transdiagnostic
vulnerabilities) to account for problematic substance use given the very low level of trait anxiety
exhibited in the sample. That is, individuals with normative levels of anxiety would not
necessarily engage in the posited negative reinforcement cycle for substance abuse (i.e.,
NMUPD). Alternatively, it is possible that these constructs simply do not serve as mediators to
the relation of anxiety and NMUPD in this sample.
It is unclear why none of the primary study variables or substance use variables were
associated with one another, but there are several possible explanations. First, this may indicate
that the current sample of college students is atypical compared to those reported in extant
literature in regard to substance use rates. Indeed, alcohol use in this sample was markedly lower
than the national average for college students (9.2% in the current sample compared to 31.6%;
Knight et al., 2002). Similarly, the rate of past-year marijuana use among college students in a
large, representative survey was higher than in the current study (30% compared to 16.5%,
respectively; Mohler-Kuo, Lee, & Wechsler, 2003). Considering that this sample is, on average,
on the low end of emerging adulthood, it is possible that they may behave more like high school
students than college students. However, a sample of high school students who reported drinking
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alcohol in the past 30 days evidenced higher rates (44.9%; Miller, Naimi, Brewer, & Jones,
2007) than in the current sample of college students. Alternatively, the setting of the current
study, which ran up to 10 participants at a given time, may have contributed to potential sample
bias due to perceived lack of anonymity.
Limitations
Within the current study, several limitations warrant consideration. A potential chief
limitation is the way in which NMUPD was operationally defined as it may have limited
generalizability of the results to the overall population of undergraduate students who engage in
NMUPD. In the current study, a broad definition of NMUPD was used to capture all behaviors
that are associated with misuse of prescription drugs and is consistent with definitions provided
by both NIDA and SAMHSA. Specifically, NMUPD was defined as using prescription
medication “from a source other than your own prescription, beyond the amount you were told to
take, or for some reason other than prescribed,” and examples were provided to orient
participants (i.e., “some of the common ways include taking stimulants to stay up at night, taking
Xanax to feel good, or taking a leftover pain pill for an ache that it was not specifically
prescribed for”). This definition is consistent with literature that describes misuse of medication
that was prescribed to the individual, using medication from any source other than a provider,
and using for a nonmedical or recreational purpose (see Holloway & Bennett, 2012; Kelly et al.,
2015). In contrast, other studies simply defined NMUPD as use of a prescribed medication
without a doctor’s prescription or medication that was not prescribed to them (Jeffers et al.,
2015; McCabe et al., 2005). Rates of past-year misuse are much lower in studies using this
definition (e.g., less than 30%; Jeffers et al., 2015).
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Although the measure used in this study, the Use of Prescription Drugs Questionnaire,
was based on existing definitions and research, it is not validated, and the items may have been
unclear to some participants. For instance, participants may have misunderstood items such as
frequency of prescription drug use, which was designed to be responded to only for participants
who engaged in past-year NMUPD. It may be that some participants responded to this item
regardless of nonmedical use, which might explain why the frequency of daily NMUPD is so
high (e.g., participants who are prescribed amphetamines for attention difficulties would take
them daily). Given this limitation, this measure may lack internal validity as participants may
have inconsistently responded to items on this questionnaire, which consequently limited
variability among items. As such, these results may not extend to the broader population of
students engaging in NMUPD.
A related limitation concerns the characteristics of the individuals reporting NMUPD.
Alcohol use rates were lower in the current study than observed in previous studies of college
students and high schoolers; therefore, the correlational and descriptive findings suggest that the
sample characteristics in regard to substance use may not generalize to other college-age
samples. Relatedly, the perceived anonymity in the current study may have been an issue in the
reporting of illegal activity (e.g., NMUPD, underage drinking). However, this could also point to
the complexity of prescription drug use and abuse, especially considering that the drug use group
was quite heterogeneous. For example, there was considerable variability in frequency of
NMUPD, with 29.0% of the drug use group reporting past-year NMUPD on only one occasion,
27.5% reporting monthly, and 7.2% reporting weekly. There is reason to believe that an
individual abusing prescription drugs once in the past year would be characteristically different
regarding anxiety and substance use than someone reporting weekly NMUPD. Additionally, the
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current study did not examine different classes of prescription drug abuse, but instead examined
NMUPD overall. There could be important distinctions among individuals who use stimulants,
sedatives, opioids, or a combination of the three classes. Cumulatively, these findings suggest the
importance of examining NMUPD functionally.
An additional limitation is that the sample may lack heterogeneity regarding
sociodemographic variables, specifically that the sample is mostly freshmen (71.2%), female
(75.5%), and White (71.7%). As NMUPD has been associated with older students and males
(McCabe et al., 2005), the sample may limit the generalizability of current findings. However,
the extant literature is mixed concerning sex as a risk factor (e.g., Young et al., 2012), as some
studies have found that the likelihood of NMUPD has been shown to be higher in men (Huang et
al., 2006; Lanier & Farley, 2011), others among women (Simoni-Wastila, 2000), and some
finding no significant difference between the sexes (Simoni-Wastila, Ritter, & Strickler, 2004).
Lastly, the study sample was collected from a large, southeastern public institution located in a
rural area; however, NMUPD may differ in other regions of the country or urban areas. Indeed,
McCabe and colleagues (2005) report that universities in the northeastern region of the United
States and those that have competitive admission criteria encounter higher rates of past-year and
past-month nonmedical stimulant use than other regions of the country and less competitive
admission criteria, respectively.
In addition to the aforementioned methodological and sample characteristic issues, the
primary study variables (i.e., NMUPD and transdiagnostic variables), with the exception of the
MTPT-C, were retrospective self-reports. Further, the overall low rate of trait anxiety observed
in this study and the poor reliability evidenced by the ASI-3 are limitations of the methodology
that should be examined in future work. Lastly, given the sensitive nature of illegal drug use, it
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may be possible that students were dishonest in reporting their drug use. To address this concern,
participant materials were kept in folders that were marked as “confidential” and were told that
their results would be entirely anonymous.
Future Directions and Conclusions. Overall, the results of the current study contribute
to the growing body of literature supporting the adverse outcomes associated with prescription
drug abuse, and underscore the need for future studies to hypothesize intervention efforts to
address these alarming findings. Such efforts should include a thorough screener for
polysubstance use among college students given the high rates of substance abuse in this
population. Specifically, it may be beneficial to administer screeners to students who report any
substance use, as rates of NMUPD in the current study and extant literature are higher among
students engaging in other substance use. In particular, simultaneous polysubstance use was
higher among students engaging in past-year NMUPD, suggesting this population may be at
increased risk for risky substance use behaviors compared to students who do not abuse
prescription drugs.
Regarding future research endeavors, the null findings and methodological limitations of
the current study highlight key areas for consideration in future studies. An important next
direction would be examining the role of the transdiagnostic factors as mechanisms in the
relation of anxiety and NMUPD in an anxious sample. Certainly, results would be strengthened
if anxiety and NMUPD were assessed via clinical interview to determine whether symptoms
reach clinical significance, or other non-retrospective method such as ecological momentary
assessment to measure substance use behaviors and emotional experiences presently. Additional
studies should consider use of such methodology for making inferences to individuals with
anxiety symptoms that reach clinical significance, and to better assess NMUPD severity and
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impairment. If using self-report, future studies would benefit from a validated measure of
NMUPD that is not exclusive to one class of prescribed medication, and should consider rates in
the context of the definition of NMUPD that is being used. In addition, independent examination
of various classes of prescription drugs is warranted in order to identify unique characteristics
associated with a particular class of prescribed medication. Given the sensitive nature of illegal
prescription drug use, future studies would benefit from increasing the appearance of anonymity,
potentially by placing screen dividers between participants. Lastly, use of a larger, longitudinal
sample is warranted to determine temporal and causal conclusions regarding anxiety and
NMUPD.
The current study expands on the extant literature regarding correlates of past-year
NMUPD in college students, an at risk population. As rates of NMUPD are increasing among
college students, it is important to understand risk factors and risky behavior that are associated
with prescription drug abuse. Although the results of the current study do not indicate that
anxiety is a risk factor for past-year NMUPD in college students, they do suggest that
prescription drug abusers engage in higher rates of risky behavior including other substance
abuse and simultaneous polysubstance use. As such, future studies are called upon to further
examine the risk factors and associated risky behaviors associated with NMUPD among college
students.
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Select the appropriate answer.
6. How often during the last year have
you been unable to remember what
happened the night before because
you had been drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

1. How often do you have a drink
containing alcohol?
(0) Never (Skip to Questions 9-10)
(1) Monthly or less
(2) 2 to 4 times a month
(3) 2 to 3 times a week
(4) 4 or more times a week
2. How many drinks containing alcohol
do you have on a typical day when
you are drinking?
(0) 1 or 2
(1) 3 or 4
(2) 5 or 6
(3) 7, 8, or 9
(4) 10 or more

7. How often during the last year have
you needed an alcoholic drink first
thing in the morning to get yourself
going after a night of heavy
drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

3. How often do you have six or more
drinks on one occasion?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

8. How often during the last year have
you had a feeling of guilt or remorse
after drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

4. How often during the last year have
you found that you were not able to
stop drinking once you had started?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

9. Have you or someone else been
injured as a result of your drinking?
(0) No
(2) Yes, but not in the last year
(4) Yes, during the last year

5. How often during the last year have
you failed to do what was normally
expected from you because of
drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily

10. Has a relative, friend, doctor, or
another health professional
expressed concern about your
drinking or suggested you cut down?
(0) No
(2) Yes, but not in the last year
(4) Yes, during the last year
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APPENDIX B: ANXIETY SENSITIVITY INDEX – 3
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Please circle the number that best corresponds to how much you agree with each item. If any
items concern something that you have never experienced (e.g., fainting in public) answer on the
basis of how you think you might feel if you had such an experience. Otherwise, answer all items
on the basis of your own experience. Be careful to circle only one number for each item and
please answer all items.
Very
A
Very
Some Much
little
little
much
1. It is important for me not to appear nervous.
0
1
2
3
4
2. When I cannot keep my mind on a task, I
0
1
2
3
4
worry that I might be going crazy.
3. It scares me when my heart beats rapidly.
0
1
2
3
4
4. When my stomach is upset, I worry that I
0
1
2
3
4
might be seriously ill.
5. It scares me when I am unable to keep my
0
1
2
3
4
mind on a task.
6. When I tremble in the presence of others, I
0
1
2
3
4
fear what people might think of me.
7. When my chest feels tight, I get scared that I
0
1
2
3
4
won’t be able to breathe properly.
8. When I feel pain in my chest, I worry that I
0
1
2
3
4
am going to have a heart attack.
9. I worry that other people will notice my
0
1
2
3
4
anxiety.
10. When I feel “spacey” or spaced out I worry
0
1
2
3
4
that I may be mentally ill.
11. It scares me when I blush in front of people.
0
1
2
3
4
12. When I notice my heart skipping a beat, I
worry that there is something seriously wrong
0
1
2
3.
4
with me.
13. When I begin to sweat in a social situation, I
0
1
2
3
4
fear people will think negatively of me.
14. When my thoughts seem to speed up, I worry
0
1
2
3
4
that I might be going crazy.
15. When my throat feels tight, I worry that I
0
1
2
3
4
could choke to death.
16. When I have trouble thinking clearly, I worry
0
1
2
3
4
that there is something wrong with me.
17. I think it would be horrible for me to faint in
0
1
2
3
4
public.
18. When my mind goes blank, I worry there is
0
1
2
3
4
something terribly wrong with me.
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APPENDIX C: COLLEGE STUDENT’S STRESSFUL EVENT CHECKLIST
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Rank:
1
2
3
4
5
6

Value: Happened: Score:
100
73
65
63
63
58

7

50

8
9

47
45

10
11
12

45
44
40

13

39

14
15

39
39

16

39

17
18
19

37
37
36

20
21
22

35
31
30

23
24
25
26
27
28

29
29
29
28
26
26

29
30
31
32

25
24
23
20
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Life Event:
Death of a close family member
Death of a close friend
Divorce between parents
Serious legal problems
Major personal injury or illness
Responsibilities for others, such
as children/spouse
Threat to major source of
income
Difficulty with roommate(s)
Change in health of a family
member
Pregnancy
Sexual problems
Serious disagreements with
parents
Change in lifestyle for financial
reasons
Difficulty in identifying a major
Serious argument with close
family member
Problems with a girlfriend or
boyfriend
Having to repeat a course
Increased workload at school
Outstanding personal
achievement
First semester in college
Change in living conditions
Serious disagreements with an
instructor
Lower grades than expected
Change in sleeping habits
Change in social habits
Change in eating habits
Chronic car problems
Change in number of family get
togethers
Too many missed classes
Change in plans for a major
Dropped more than one class
Minor traffic violations

APPENDIX D: DEPRESSION ANXIETY STRESS SCALE – 21 – ANXIETY
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INSTRUCTIONS: Please read each statement and choose the number which indicates how
much the statement applied to you over the past week. There are no right or wrong answers.
Do not spend too much time on any statement. The rating scale is as follows:
0 = Did not apply to me at all
1 = Applied to me some degree, or some of the time
2 = Applied to me a considerable degree, or a good part of the time
3 = Applied to me very much, or most of the time

Did not
apply to
me

1. I was aware of dryness in my
mouth.
2. I experience breathing
difficulty (e.g., excessively rapid
breathing, breathlessness in the
absence of physical exertion).
3. I experienced trembling (e.g.,
in the hands).
4. I was worried about situations
in which I might panic and make
a fool of myself.
5. I felt I was close to panic.

6. I was aware of the action of
my heart in the absence of
physical exertion (e.g., sense of
heart rate increase, heart missing
a beat).
7. I felt scared without any good
reason.

Applied to Applied to
me some
me a
degree, or considerable
some of
degree, or a
the time
good part of
the time

Applied to me
very much, or
most of the
time

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3
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APPENDIX E: DIFFICULTIES IN EMOTION REGULATION SCALE – IMPULSE
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Please indicate how often the following statements apply to you by filling in the appropriate
numbered bubble from the scale below:
1=almost never (0-10%); 2=sometimes (11-35%); 3=about half the time (36-65%); 4=most of
the time (66-90%); 5=almost always (91-100%).
Almost
About half
Most of the
Almost
Sometimes
never
the time
time
always
1. I experience my
emotions as
1
2
3
4
5
overwhelming and
out of control.
2. When I’m
upset, I become
1
2
3
4
5
out of control.
3. When I’m upset,
I feel out of
1
2
3
4
5
control.
4. When I’m upset,
I feel like I can
1
2
3
4
5
remain in control
of my behaviors.
5. When I’m upset,
I have difficulty
1
2
3
4
5
controlling my
behaviors.
6. When I’m upset,
I lose control over
1
2
3
4
5
my behaviors.
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APPENDIX F: DISTRESS TOLERANCE SCALE
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Directions: Think of times that you feel distress or upset. Select the item that best describes your
beliefs about feeling distressed or upset.

1. Feeling distressed or upset is
unbearable to me.
2. When I feel distress or upset, all I
can think about is how bad I feel.
3. I can’t handle feeling distressed or
upset.
4. My feelings of distress are so intense
that they completely take over.
5. There’s nothing worse than feeling
distressed or upset.
6. I can tolerate being distressed or
upset as well as most people.
7. My feelings of distress or being
upset are not acceptable.
8. I’ll do anything to avoid feeling
distressed or upset.
9. Other people seem to be able to
tolerate feeling distress or upset
better than I can.
10. Being distressed or upset is always
a major ordeal for me.
11. I am ashamed of myself when I feel
distressed or upset.
12. My feelings of distress or being
upset scare me.
13. I’ll do anything to stop feeling
distressed or upset.
14. When I feel distressed or upset, I
must do something about it
immediately.
15. When I feel distressed or upset, I
cannot help but concentrate on how
bad the distress actually feels.

Agree
and
Mildly Strongly
Disagree Disagree Disagree
Equally

Strongly
Agree

Mildly
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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APPENDIX G: MARLOWE-CROWNE SOCIAL DESIRABILITY SCALE – SHORT FORM
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Instructions: Listed below are a number of statements concerning personal attitudes and traits.
Read each item and decide whether the statement is true or false as it pertains to you.

1. It is sometimes hard for me to go on with my work if I am not encouraged.

True

False

2. I sometimes feel resentful when I don’t get my own way.

True

False

3. On a few occasions, I have given up doing something because I thought too
little of my ability.

True

False

4. There have been times when I felt like rebelling against people in authority
even though I knew they were right.

True

False

5. No matter who I’m talking to, I’m always a good listener.

True

False

6. There have been occasions when I took advantage of someone.

True

False

7. I’m always willing to admit it when I make a mistake.

True

False

8. I sometimes try to get even, rather than forgive and forget.

True

False

9. I am always courteous, even to people who are disagreeable.

True

False

True

False

10. I have never been irked when people expressed ideas very different from
my own.
11. There have been times when I was quite jealous of the good fortune of
others.
12. I am sometimes irritated by people who ask favors of me.

True

False

True

False

13. I have never deliberately said something that hurt someone’s feelings.

True

False
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APPENDIX H: NONMEDICAL PRESCRIPTION DRUG MOTIVES QUESTIONNAIRE

71

Below is a list of reasons people sometimes give for nonmedical prescription drug use. Think
about all of the times that you have used prescription drugs nonmedically and indicate how often
you have done so for each of the below reasons.
Almost
Almost
Some of the Half of the
Most of
Always/
Never/Never
Time
Time
the Time
Always
1. Because your
friends pressure you
1
2
3
4
5
to use them
2. Because it helps
you when you feel
1
2
3
4
5
depressed or nervous
3. To be sociable

1

2

3

4

5

4. So that others
won’t kid you about
not doing it

1

2

3

4

5

5. To get high

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

9. Because it’s fun

1

2

3

4

5

10. To be liked

1

2

3

4

5

11. To manage pain

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

6. Because it gives
you a pleasant feeling
7. Because it
improves parties and
celebrations
8. To forget about
your problems

12. To be more
efficient
13. To escape from
your life
14. To help you stay
organized
15. To perform better
on school work or on
tests
16. Because it helps
to increase your
alertness
17. To help you sleep
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18. To help focus
19. Because you
didn’t want to be the
only one not doing it
20. Because it
counteracts the
effects of other drugs

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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APPENDIX I: USE OF PRESCRIPTION DRUGS QUESTIONNAIRE
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Doctors sometimes prescribe medicine to calm people down or to help them relax their muscles,
to help people sleep, deal with pain, or lose weight. Besides the medical uses, people sometimes
take these pills on their own without the direction of a doctor or recreationally. This is
sometimes called “nonmedically,” which means from a source other than your own prescription,
beyond the amount you were told to take, or some reason other than prescribed. For instance,
some of the common nonmedical or recreational uses include taking stimulants to stay up at
night, taking Xanax to feel good, or taking a leftover pain pill for an ache that it was not
specifically prescribed for.
Instructions: Please answer the following questions pertaining to past year prescription drug
use.
1. Check the boxes of any medication(s) you use, either prescribed or non-prescribed.
Stimulants (e.g., amphetamines: Adderall [speed]; Ritalin [Vitamin R], Vyvanse,
“bennies,” “uppers”)
o Type (if known):
_______________________________________________________________
Sedatives (e.g., anxiolytics: Ativan, Klonopin, Valium, Xanax [bars], “barbs,”
“benzos,” “downers,” “tranks;” sleeping pills: Ambien
o Type (if known):
_______________________________________________________________
Opioid painkillers (e.g., Codeine [cody, Purple Drank], Hydrocodone/Lortab/Vicodin
[hydro, norco, tabs, vike], Oxycodone/OxyContin/Percocet [oxy, percs])
o Type: (if known):
_______________________________________________________________
Other
_____________________________________________________________________
2. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription
medications that were not prescribed to you?
YES NO
3. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription
medications beyond the amount you were told to take (either in a day or in one dose)?
YES NO
4. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription
medications for reasons other than prescribed?
YES NO
5. If yes to any of the above, what
medication(s)?
______________________________________________________________________________
5a. In what circumstances do you use stimulants?
Social (e.g., partying or pregaming, enhancement of good mood)
Academic (e.g., to stay up later, enhance studying)
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Coping (e.g., to relieve stress or anxiety, reduce bad mood)
Other
_____________________________________________________________________
None
5b. In what circumstances do you use sedatives?
Social (e.g., partying or pregaming, enhancement of good mood)
Academic (e.g., to stay up later, enhance studying)
Coping (e.g., to relieve stress or anxiety, reduce bad mood)
Other
_____________________________________________________________________
None
5c. In what circumstances do you use opioid painkillers?
Social (e.g., partying or pregaming, enhancement of good mood)
Academic (e.g., to stay up later, enhance studying)
Coping (e.g., to relieve stress or anxiety, reduce bad mood)
Other
_____________________________________________________________________
None
6. In the past 12 months, how much have you used prescription medications recreationally or
nonmedically?
0
Never

1
Once

2
Monthly

3
Weekly

4
2-3 days
per week

5
Daily

6
Multiple
times a
day

Other:

Dose can mean both the dosage prescribed (i.e., the amount in milligrams) and the frequency
taken (i.e., amount of times used per day, week, etc.). Refer to the medication information sheet
for standard dosages.
7. When you are using prescription drugs, how much, on average, do you take?
6
5
4
3
2
1
More than
1.5 times the Twice the
Prescribed
½ of the
Less than
twice the
prescribed
prescribed
dosage
prescribed
½ the
prescribed
dosage
dosage
dosage
prescribed
dosage
dosage
8. Do you ever use prescription drugs simultaneously with any other substance including
alcohol, marijuana, other prescription drugs, or any other illicit drugs?
YES NO
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8a. If so, which substance(s)?
________________________________________________________________________

9. Over the past year, has your use of prescription drugs been associated with feeling a strong
desire or urge to use?
YES NO
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APPENDIX J: SOCIODEMOGRAPHIC QUESTIONNAIRE AND GENERAL MEDICAL
HISTORY
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1. Sex
a. Male
b. Female
c. Transgender
2. Age _____________
3. Date of birth _____________
4. Ethnicity
a. Not Hispanic or Latino
b. Hispanic or Latino
5. Race
a.
b.
c.
d.
e.
f.
g.

White
Black or African American
Asian
Native Hawaiian or Other Pacific Islander
Native American/Alaska Native
Biracial
Other: __________________________

6. Year in school
a. Freshman (1st year)
b. Sophomore (2nd year)
c. Junior (3rd year)
d. Senior (4th year)
e. Other: __________________________
7. Current GPA: _____________
8. Number of courses enrolled in this semester: _____________
9. Major: __________________________
10. Living Status
a. On-campus dorm
b. Greek-affiliated house
c. Off-campus apartment or house
d. Other: __________________________

11. Do you live:
a. With friends
b. With family
79

c. By yourself
12. Indicate which of the following applies to you:
a. I have the University of Mississippi’s student health insurance.
b. I have health insurance through the state’s Children’s Health Insurance Program
(CHIP).
c. I am on my parents’ or another guardian’s health insurance.
d. I do not have health insurance.
13. Please indicate how many days you have used each of the following substances in the
past year. Also, please indicate if you have EVER used the substance in your lifetime
(SELECT THE APPROPRIATE BOX FOR EACH QUESTION.)
How often did you use this substance in the PAST
YEAR?

Never
a. Alcohol
b. Caffeine
c. Cigarettes or
other tobacco
d. Marijuana (pot,
weed), hashish
(hash)
e. Cocaine (crack,
coke, rock)
f. Heroin
g.
Methamphetamine
(crank, ice, meth)
h. Hallucinogens
(LSD, mescaline,
peyote, mushrooms,
psilocybin, etc.)
i. PCP (angel dust)
or Ketamine (“K”)
j. Ecstasy (X), GHB
(Liquid X), or
Rohypnol (roofie)

1
1

Less
Daily/Almost
Monthly Weekly
than
daily
monthly
2
3
4
5
2
3
4
5

Have you
EVER used
this
substance in
your
lifetime?
Yes

No

1
1

2
2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2

1

2

3

4

5

1

2
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1.

Do you have or have you ever had any of the following medical conditions?
Current?

a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
l.
m.
n.
o.
p.
q.
r.
s.
t.

Approximate
Date of Diagnosis

w.

Heart Attack
yes
Angina (chest pain on exertion) yes
Irregular Heart Beat
yes
Other Heart Problems
yes
Stroke
yes
Dizziness/Fainting Spells
yes
High Blood Pressure
yes
High Cholesterol
yes
Thyroid Problems
yes
Cancer
yes
Kidney Problems
yes
Liver Problems
yes
Gout
yes
Diabetes
yes
Emotional/Psychiatric Problems yes
Drug/Alcohol Problems
yes
Arthritis
yes
Emphysema
yes
Seizure Disorder
yes
Head injury with
loss of consciousness
yes
Cognitive impairment
yes
Respiratory or Lung Problem
(e.g., Asthma, Bronchitis)
yes
Immune disorder
yes

2.

If you answered ″yes″ to any of the above medical conditions, please describe:

u.
v.

no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no

__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________

____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________
____________

no
no

__________
__________

____________
____________

no
no

__________
__________

____________
____________

Problem: _________________________________________________________
Treatment Received: _________________________________________
Problem: _________________________________________________________
Treatment Received: _________________________________________
Problem: _________________________________________________________
Treatment Received: _________________________________________
3.

Do you have a personal physician?
If yes, when was your last visit? ________________

YES

NO

4.

Do you have a personal psychiatrist?
If yes, when was your last visit? ________________

YES

NO

5.

Have you ever been in therapy?

YES

NO
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5a. If yes, what was the therapy for (e.g., stress, depression, anxiety, anger)?
________________________________________________________________________
5b. Are you currently in therapy?

YES

NO

5c. If no, when were you in therapy?
________________________________________________________________________
6.

Please list all medications that you are currently taking on a regular basis:
MEDICATION
REASON FOR TAKING
_____________________
_______________________
_____________________
_______________________
_____________________
_______________________
_____________________
_______________________

7.

Have you ever taken any medication for mood?
YES

NO

If yes, please list which medication(s):
Medication:___________________ Dose: ____________________
Medication:___________________ Dose: ____________________
Medication:___________________ Dose: ____________________
Medication:___________________ Dose: ____________________
8.

Do you or have you had a prescription for stimulants, sedatives, or opioid painkillers?
YES NO
If yes,
What stimulant? __________________________
Dose: ________________
What sedative? ___________________________
Dose: ________________
What opioid painkiller? ____________________
Dose: ________________
8a. Do you have a current (or have you in the past year) prescription?

YES

NO

8b. What were the doctor’s instructions?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
8c. Do you take the medication as prescribed (e.g., dose, frequency)?

YES

NO

8d. How do you use the
medication?
______________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
9.

Please list any herbal or over-the-counter medications that you take regularly:
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________________________________________________________________________
________________________________________________________________________
10.

Please list any operations/surgeries that you have had:
Procedure:___________________________
Procedure:___________________________
Procedure:___________________________

11.

Date:_____________
Date:_____________
Date:_____________

Is there anything else about your health status that you think might be important or useful
to tell us?
YES NO

If yes, please explain:
______________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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APPENDIX K: GROUP ASSIGNMENT FORM
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#1 NOT
endorsed

#1 endorsed

#s 2, 3, or 4 = YES

#s 2-4 = NO

#5 = social,
academic, or
coping is selected

#8 on
Health
Questionnai
re = YES

#6 = anything
other than 0
Medical Use

#8 = YES
Non-Drug
Use Group

NMUPD

Drug Group
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Table 1. Point-Biserial Correlations of NMUPD and Study Variables

87

1
2
3
4
5
6
7
1. NMUPD
–
2. ASI-3
.030
–
3. DASS-21-A
.120
.363*** –
4. DERS-Impulse .132
.309*** .559*** –
5. DTS
-.103
-.465*** -.405*** -.573*** –
6. Quit latency
-.046
-.004
-.135
-.147*
.060
–
7. AUDIT
.401*** .058
.094
.061
-.050
-.198** –
8. Illicit drug use .373*** .077
.183*
.096
-.120
-.075
.371***
Mean
–
15.97
1.89
11.77
48.66
63.24
2.54
SD
–
4.90
3.34
5.10
12.50
80.46
3.16
n
184
184
184
184
184
180
184
Note. ASI-3 = Anxiety Sensitivity Index – 3; AUDIT = Alcohol Use Disorders Identification Test;
DASS-21-A = Depression Anxiety Stress Scale – 21 – Anxiety subscale; DERS-Impulse =
Difficulties in Emotion Regulation Scale – Impulse subscale; DTS = Distress Tolerance Scale;
NMUPD = nonmedical use of prescription drugs; Quit latency = quit latency of Mirror Tracing
Persistence Task in seconds.
*p < .05, **p < .01, ***p < .001

8

–
0.33
0.86
168

Table 2. Between Group Differences on Study Variables

M

NMUPD
SD
n

M

Non-NMUPD
SD
n

d

95% CI for
Mean
Difference
[-1.78 – 1.18]
[-1.77 – 1.18]

t

p

df
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ASI-3
16.16
4.51 69
15.86
5.14 115 0.06
-0.399
.690
182
DASS-212.41
3.81 69
1.58
2.99 115 0.24
-1.533
.128
118
Anxiety
DERS12.64
5.71 69
11.25
4.65 115 0.27
[-2.91 – 0.14] -1.793
.075
182
Impulse
DTS
47.00
13.10 69
49.66 12.07 115 0.21
[-1.09 – 6.41] 1.402
.163
182
Quit
58.46
72.28 68
66.14 85.23 112 0.10 [-16.77 – 32.13] 0.620
.536
178
latency
CSSEC
405.04 181.39 69 415.83 182.98 115 0.06 [-44.02 – 65.58] 0.388
.698
182
Diversity of
2.14
1.67 64
0.71
0.97 103 1.05
[-1.83 – -1.03] -7.020 < .001
165
drug use
AUDIT
4.17
3.55 69
1.57
2.44 115 0.86
[-3.57 – -1.65] -5.393 < .001
106.80
Poly0.41
0.50 68
0.05
0.21 115 0.97
[-0.49 – -0.24] -5.838 < .001
80.72
substance
use
Note. ASI-3 = Anxiety Sensitivity Index – 3; AUDIT = Alcohol Use Disorders Identification Test; CSSEC = College
Student Stressful Event Checklist; DASS-21-A = Depression Anxiety Stress Scale – 21 – Anxiety subscale; DERSImpulse = Difficulties in Emotion Regulation Scale – Impulse subscale; DTS = Distress Tolerance Scale; NMUPD =
nonmedical use of prescription drugs; Quit latency = quit latency of Mirror Tracing Persistence Task in seconds.
Diversity of drug use includes alcohol and illicit drugs and excludes tobacco and prescription drugs.
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Anxiety
Sensitivity

b1

a1
c

Anxiety

’

a2

NMUPD

b2
Distress Tolerance

a3

b3
Emotion-driven
impulse control
difficulties

Figure 1. Conceptual diagram of the proposed multiple parallel mediation model
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Conditional Indirect Effects: Anxiety sensitivity (-.0098), distress tolerance
(.0131), and Emotion-driven impulse control difficulties (.0258)

Anxiety sensitivity

Anxiety

.0652

NMUPD

Distress tolerance

Emotion-driven
impulse control
difficulties

Figure 2. Multiple mediation model of the relation between anxiety and NMUPD, with selfreported anxiety sensitivity, distress tolerance, and emotion-driven impulse control difficulties.
Note. The unstandardized regression coefficients for each path of the model are reported.
*p < .001
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Conditional Indirect Effects: Anxiety sensitivity (-.0082), distress tolerance via
latency to quit (.0018), and Emotion-driven impulse control difficulties (.0433)

Anxiety Sensitivity

Anxiety

.0369

NMUPD

Distress Tolerance

Emotion-driven
impulse control
difficulties

Figure 3. Multiple mediation model of the relation between anxiety and NMUPD, with selfreported anxiety sensitivity and emotion-driven impulse control difficulties, and behaviorally
measured distress tolerance.
Note. The unstandardized regression coefficients for each path of the model are reported.
*p < .001
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